BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $520,911 | +1.8% | 73,575 | +1.2% | 0.02% | +11.1% |
| Q2 2023 | $511,611 | -15.2% | 72,672 | +0.5% | 0.02% | -28.0% |
| Q1 2023 | $603,165 | -26.9% | 72,322 | +0.6% | 0.02% | -28.6% |
| Q4 2022 | $825,492 | -9.0% | 71,907 | -0.1% | 0.04% | -25.5% |
| Q3 2022 | $907,000 | +20.8% | 71,947 | +1.3% | 0.05% | +23.7% |
| Q2 2022 | $751,000 | -32.8% | 70,999 | +3.3% | 0.04% | -34.5% |
| Q1 2022 | $1,118,000 | +23.3% | 68,761 | +5.0% | 0.06% | +38.1% |
| Q4 2021 | $907,000 | +19.8% | 65,472 | +24.3% | 0.04% | +27.3% |
| Q3 2021 | $757,000 | -5.4% | 52,671 | +4.1% | 0.03% | -5.7% |
| Q2 2021 | $800,000 | +52.1% | 50,605 | -2.2% | 0.04% | +40.0% |
| Q1 2021 | $526,000 | +96.3% | 51,762 | +44.0% | 0.02% | +78.6% |
| Q4 2020 | $268,000 | +415.4% | 35,950 | +139.7% | 0.01% | +366.7% |
| Q3 2020 | $52,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |